TQB2858 + gemcitabine + cisplatin

TQB2858 + gemcitabine + cisplatin is a combination regimen under clinical investigation mainly for advanced or refractory sarcomas and potentially for other solid tumors. **TQB2858** is a bifunctional fusion protein consisting of a monoclonal antibody against PD-L1 (programmed death-ligand 1) fused to the extracellular domain of the TGF-β receptor; it inhibits both PD-L1-mediated immune suppression and TGF-β-driven tumor-promoting processes[1][3][4]. **Gemcitabine** is a nucleoside analog that inhibits DNA synthesis, functioning primarily as an antimetabolite. **Cisplatin** is a platinum-based chemotherapy agent that causes cross-linking of DNA, leading to apoptosis of rapidly dividing tumor cells. The combination aims to enhance anti-tumor immune responses via immune checkpoint blockade while providing cytotoxic activity through traditional chemotherapeutics. The regimen is being evaluated in patients with refractory or metastatic sarcomas, such as osteosarcoma and alveolar soft part sarcoma, in phase 1b clinical studies[1][3].